CAR-T Therapy, the End of a Chapter or the Beginning of a New One?
School of Cancer & Pharmaceutical Sciences, Faculty of Life & Sciences & Medicine, King’s College, London SE1 9NH, UK
ASYS Pharmaceutical Consultants-APC Inc 2, Bedford, NS B4A 4L2, Canada
Academic Editors: Avery D. Posey and Kole T. Roybal
Received: 30 January 2021 / Revised: 14 February 2021 / Accepted: 14 February 2021 / Published: 18 February 2021
CAR-T therapy is a breakthrough treatment in our fight against cancer. It was recently approved for the treatment of advanced diffuse large B-cell lymphoma and acute lymphoblastic leukaemia after the failure of previous multiple therapies. The positive results achieved in the registration studies for those patients were remarkable. Unfortunately, this was not the end of this chapter. Disease relapses occur in the range of 30–60% of patients treated with CAR-T therapy. Cytokine release syndrome represents a major side effect for treatment with CAR-T therapy. Notwithstanding, the high positive results triggered the start of a huge research activity of CAR-T therapy in other haematologic malignancies such as acute myelogenous leukaemia, Hodgkin’s disease, chronic lymphocytic leukaemia, and multiple myeloma. The research is also trying to overcome the hurdles stated above. These activities represent a new chapter in the management of haematologic malignancies with CAR-T therapy.